Loxapine Succinate

   
Google
 
Web NewDrugInformation.com

Loxapine Succinate


Drug - Loxapine Succinate
The trade name of the product as shown on the labeling.

Dosage - CAPSULE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Loxapine Succinate
Multiple ingredients are in alphabetical order.

Strength - EQ 25MG BASE
The potency of the active ingredient(s), Loxapine Succinate. May repeat for multiple part products.

Applicant - WATSON LABS
The firm name holding legal responsibility for Loxapine Succinate. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 072206
The FDA assigned number to Loxapine Succinate. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Loxapine Succinate. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code - AB
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jun 15, 1988
The date Loxapine Succinate was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Loxapine Succinate. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Loxapine Succinate is in. Format is RX, OTC, DISCN.

Applicant Full Name - Watson Laboratories Inc
The full name of the firm holding legal responsibility for the new application of Loxapine Succinate.

Loxapine Succinate